KUALA LUMPUR, Dec 13 (Bernama) -- AGC Biologics, a global biopharmaceutical contract development and manufacturing organisation (CDMO), has collaborated with W. L. Gore & Associates (Gore) to feature a new protein A affinity purification technology from Gore alongside AGC Biologics’ contract manufacturing services for antibody therapies.
In a statement, AGC Biologics said that investments in new technologies like the Gore protein capture device are important to meet its client's needs, and to address changes in the monoclonal antibody market.
“We are excited to offer this new technology for good manufacturing practices at relevant scales throughout our manufacturing network,” AGC Biologics chief technical officer Kasper Moller said.
The company said that by using Gore and AGC Biologics services, biopharmaceutical companies can improve downstream purification processes through increased productivity of the protein A step, enabling a full single-use downstream process.
“This can eliminate column bioburden from storage, reduce manufacturing footprint, help lower costs for clinical manufacturing, and select scale commercial manufacturing.
“The collaboration includes the family of Gore protein capture devices with protein A, which improves productivity in protein A affinity purification, and provides high binding capacity at short residence times, alongside AGC Biologics’ monoclonal antibody-based CDMO services,” it said.
The joint offering from Gore and AGC Biologics is available across various sites in the AGC Biologics’ network.
AGC Biologics has established more than 200 mammalian and microbial cell culture-based products, in addition to decades of research and development experience in the monoclonal antibody space.
-- BERNAMA
No comments:
Post a Comment